Clinical Trials Logo

Filter by:
NCT ID: NCT06020898 Recruiting - Clinical trials for Acute Ischemic Stroke

Sodium Valproate in Patients With Acute Ischemic Stroke

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this pilot trial is to investigate the feasibility, safety, and efficacy of sodium valproate in patients with acute ischemic stroke, and also explore the mechanism: whether valproate increases peripheral anti-inflammatory CD177+ neutrophil levels.

NCT ID: NCT06020885 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT, and to investigate the treatment-related toxicities and quality of life of the new regimen.

NCT ID: NCT06020690 Recruiting - Chronic Sinusitis Clinical Trials

A Clinical Study to Evaluate the Safety and Effectiveness of Novabel Bioabsorbable Steroid-releasing Stent for the Chronic Sinusitis

Start date: August 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the safety and effectiveness of Novabel bioabsorbable steroid-releasing stent in chronic sinusitis. The main questions it aims to answer are: - The safety of this device for the chronic sinusitis - The effectiveness of this device for the chronic sinusitis Participants will be implanted bioabsorbable steroid-releasing stents after FESS surgery. Participants will be asked to be back to the clinic for follow-up 14 days, 30 days, 90 days, 180 days and 360 days after procedure. Researchers will compare test device and marketed device to see if the safety and effectiveness between these two devices are non-inferior.

NCT ID: NCT06020469 Recruiting - Anesthesia Clinical Trials

Comparative Effects of Ciprofol and Propofol on Pain Intensity on the First Day After Surgery: a Retrospective, Propensity Score Matched, Cohort Study

Start date: October 2023
Phase:
Study type: Observational

Data intelligence platform was widely used to facilitate the process of clinical research. However, a platform that integrates natural language processing (NLP) and machine learning (ML) algorithms has not been reported in perioperative medical management.

NCT ID: NCT06020430 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Start date: February 8, 2024
Phase: N/A
Study type: Interventional

Radical radiotherapy is critical for locally advanced non small cell lung cancer(NSCLC ). Our previous sturdy indicated that patients who received induction immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis.Grade 2 or more pneumonitis patients have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting CTV radiation is feasible for patients undergoing concurrent radio-chemotherapy for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to induction therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.

NCT ID: NCT06020352 Recruiting - NSCLC Clinical Trials

The Efficacy and Safety of KN046 Combined With Axitinib

Start date: August 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation of the efficacy of KN046 combined with acitinib as a neoadjuvant therapy for resectable NSCLC through primary pathological response rate and surgical resection rate

NCT ID: NCT06020326 Recruiting - HFRS Clinical Trials

A Retrospective Cohort Study of HFRS

Start date: May 5, 2022
Phase:
Study type: Observational

The goal of this retrospective cohort study is to learn about the clinial characteristics of HFRS patients, explore the risk factors of the occurrence and death of HFRS, and build a risk prediction model for HFRS.

NCT ID: NCT06020144 Recruiting - Clinical trials for Rheumatoid Arthritis

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

TARA
Start date: November 15, 2023
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate response or intolerance to Biologic DMARDs.

NCT ID: NCT06020066 Recruiting - Clinical trials for Non-small Cell Lung Cancer

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Start date: August 10, 2023
Phase: Phase 2
Study type: Interventional

Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis. This study aims to evaluate the efficacy and safety of stereotactic radiotherapy for oligo-residual intracranial disease after first-line third-generation EGFR Inhibitors.

NCT ID: NCT06019936 Recruiting - Clinical trials for Drug-Induced Liver Injury

A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects

Start date: August 10, 2023
Phase: Phase 2
Study type: Interventional

The goal of this randomized, double-blind, placebo controlled, Multicenter Phase II clinical trial is to initially evaluate the Safety and Efficacy of MT2004 Capsule in Cholestatic and Mixed drug induced liver injury (DILI) subjects. The main questions it aims to answer are: 1. The Efficacy of MT2004 Capsule in Cholestatic and Mixed DILI subjects 2. The Safety and Pharmacokinetic characteristic of MT2004 Capsule in Cholestatic and Mixed DILI subjects 3. The mechanism of using MT2004 Capsule on Cholestatic and Mixed DILI subjects